Evaluation of sixteen anti-motion sickness drugs under controlled laboratory conditions.
D000293:Adolescent; D000328:Adult; D000661:Amphetamine / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003501:Cyclizine / Q000627:therapeutic use; D004111:Dimenhydrinate / Q000627:therapeutic use; D004357:Drug Synergism; D004809:Ephedrine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008468:Meclizine / Q000627:therapeutic use; D008620:Meprobamate / Q000627:therapeutic use; D009041:Motion Sickness / Q000188:drug therapy*; D010640:Phenothiazines / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011346:Prochlorperazine / Q000627:therapeutic use; D011398:Promethazine / Q000627:therapeutic use; D012601:Scopolamine / Q000627:therapeutic use; D013847:Thiethylperazine / Q000627:therapeutic use
D000932:Antiemetics; D001549:Benzamides; D010640:Phenothiazines; D010879:Piperazines; D010643:Phenoxybenzamine; D008468:Meclizine; D013847:Thiethylperazine; D008620:Meprobamate; D000661:Amphetamine; D012601:Scopolamine; D011398:Promethazine; D004809:Ephedrine; D004111:Dimenhydrinate; D003501:Cyclizine; D002746:Chlorpromazine; D011346:Prochlorperazine